BYSI (BeyondSpring) Accounts Payable: $0.65 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BYSI BeyondSpring Inc BYSI
25 GF Score
Price $1.26
! 1 Warning Sign
View Full Analysis

What is BeyondSpring Accounts Payable?

BeyondSpring BYSI +0.81% 25 Accounts Payable is $0.65 Mil as of Mar. 2026. GuruFocus rates BYSI with a GF Score™ of 25/100. The stock has 1 warning sign investors should review.

BeyondSpring's Accounts Payable for the quarter that ended in Mar. 2026 was $0.65 Mil.

BeyondSpring's quarterly Accounts Payable increased from Sep. 2025 ($0.30 Mil) to Dec. 2025 ($0.36 Mil) and increased from Dec. 2025 ($0.36 Mil) to Mar. 2026 ($0.65 Mil).

BeyondSpring's annual Accounts Payable declined from Dec. 2023 ($0.56 Mil) to Dec. 2024 ($0.30 Mil) but then increased from Dec. 2024 ($0.30 Mil) to Dec. 2025 ($0.36 Mil).

BeyondSpring Accounts Payable Historical Data

* Premium members only.

The historical data trend for BeyondSpring's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BeyondSpring Accounts Payable Chart

BeyondSpring Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.66 1.08 0.56 0.30 0.36

BeyondSpring Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Jun22 Dec22 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.36 0.27 0.30 0.36 0.65
BYSI
25GF Score
BeyondSpring Inc BYSI
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BeyondSpring Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $0.65 Mil mean?
BeyondSpring (BYSI) has a Accounts Payable of $0.65 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on BeyondSpring and its competitors.
Is BeyondSpring's Accounts Payable too high?
BeyondSpring's current Accounts Payable is $0.65 Mil. Overall, BeyondSpring has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does BeyondSpring's Accounts Payable compare to PLRX and MCRB?
BeyondSpring's Accounts Payable of $0.65 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on BeyondSpring and its competitors. BeyondSpring's current Accounts Payable is $0.65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeyondSpring stock overvalued right now?
BeyondSpring (BYSI) has a current Accounts Payable of $0.65 Mil. The current Accounts Payable is $0.65 Mil. BeyondSpring's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For BeyondSpring (BYSI), the current Accounts Payable is $0.65 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BeyondSpring Business Description

Address 100 Campus Drive, West Side, 4th Floor, Suite 410, Florham Park, New Jersey, NJ, USA, 07932
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.
25GF Score

Get the complete analysis for BYSI

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.26
Price